



The European Agency for the Evaluation of Medicinal Products
Directorate

London, 21 February 2003
Doc. Ref: EMEA/MB/182/03/Final

PRESS RELEASE

EMEA Management Board elects new chairman and sets out proposed work programme for 2004

The EMEA Management Board met on 20 February 2003. This is the first meeting of its fourth three-year mandate. The new membership of the Board is given in annex. The Board re-elected Dr Keith Jones (UK) as its chairman and elected Dr Philippe Duneton (France) as vice-chairman.

The Board approved the draft work programme and budget request for 2004. The key objectives and priorities for the Agency in 2004 can be summarised as follows:

Consolidation and development of existing activities	✓ Continuous improvements to core business activities, with specific monitoring through quality management and performance monitoring
New institutional environment	✓ Enlargement to 10 new Member States
Key strategic objectives	✓ Pharmacovigilance and risk management ✓ Scientific advice and protocol assistance ✓ EU telematics strategy implementation
Preparation for future business environment	✓ Preparation for future legislation (review of EU pharmaceutical legislation, paediatrics, herbal medicines) ✓ Changes to the regulatory environment (new variations regulation, generic applications in the centralised procedure)

The budget requested totals € 84 224 000 (2003: € 78 081 000), including total forecast fee revenue of € 52 700 000 (2003: € 48 142 000), a general EU subsidy request of € 17 500 000 (2003: € 15 500 000), € 3 500 000 for the orphan drug fund in 2004 (2003: € 3 300 000) and € 7 500 000 for implementation of the EU telematics strategy. An additional 27 posts are requested, that would take the total staff complement to 314. The budget and work programme will now be submitted to the EU institutions as part of the EU budget process. The Board will finally adopt the work programme and budget at the end of 2003 after voting by the European Parliament and Council of Ministers.

The next meeting of the Management Board will be on 5 June 2003.

--ENDS--

NOTES:

1. Dr Keith Jones is a medical doctor. After 22 years experience in the pharmaceutical industry, Dr Jones was appointed Chief Executive of the UK Medicines Control Agency in 1991, a position from which he retired in 2002. He joined the EMEA Management Board in 1995 and was first elected chairman in 2001.
2. Dr Philippe Duneton is a medical doctor. After having served as a member of cabinet for two French health ministers, Dr Duneton joined the French Agence du Médicament in 1998 as Secretary-General. He was appointed Director-General of the new **Agence Française de Sécurité Sanitaire des Produits de Santé** (AFSSAPS) in 1999. He joined the EMEA Management Board in 1999.

Public

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 09
E-mail: mail@emea.eu.int <http://www.emea.eu.int>

3. Elements of the EMEA draft budget 2004

Revenue side includes:

- Fee revenue of € 52 700 000 (62.5 % of revenue), with a stable number of 38 applications for new human medicines in 2004 (2003: 38), including 22 applications from designated orphan medicines. Applications in the veterinary sector are expected to increase to 14 applications for new veterinary medicines (2003: 10), with 4 applications for maximum residue limits (2003:2).
- General EU subsidy of € 17 500 000 (20.8 % of budget), plus € 7 500 000 for the EU telematics strategy in 2004 (8.9 % of revenue).
- Orphan drug fund request of € 3 500 000 (4.2 % of revenue).

Expenditure side includes:

- Payment of € 23 683 000 to national competent authorities for rapporteur, co-rapporteur and inspection services (28.1 % of expenditure).
- Staff salaries and other costs of € 36 964 000 (43.9 % of expenditure).
- Building and equipment costs of € 15 932 000 (18.9 % of expenditure).
- These 2 items include expenditure of € 7 500 000 for the EU telematic strategy.

4. This press release, together with other information about the work of the EMEA, may be found on the EMEA web site at the following location: <http://www.emea.eu.int>
5. The 2002 annual report and the 2003 work programme are available on the web site.

Media enquiries only to:

Martin Harvey Allchurch

Tel. (44-20) 74 18 84 27, Fax (44-20) 74 18 84 09, E-mail: martin.harvey-allchurch@emea.eu.int

Members of the Management Board

Fourth term of office 2003-2005

Chairman Keith JONES

Members

European Parliament	Gianmartino BENZI, José-Luis VALVERDE LÓPEZ <i>Alternates:</i> Dietrich HENSCHLER, Jean-Pierre REYNIER
European Commission	Jean-Paul MINGASSON, Fernand SAUER <i>Alternate:</i> Paul WEISSENBERG, Patricia BRUNKO
Belgium	André PAUWELS, Frans GOSSELINCKX
Denmark	Jytte LYNGBIG, Ib VALSBORG
Germany	Hans-Peter HOFMANN, Ilse-Dore SCHÜTT
Greece	Charlambos SAVAKIS, Elias MOSSIALOS
Spain	Fernando GARCÍA ALONSO, Carlos LENS CABRERA
France	Philippe DUNETON (<i>Vice-chairman</i>), Martin HIRSCH
Ireland	Tom MOONEY, Paddy ROGAN
Italy	Nello MARTINI, Gaetana FERRI
Luxembourg	Mariette BACKES-LIES, Claude HEMMER
Netherlands	Huib VAN DE DONK, Frits PLUIMERS
Austria	Christian KALCHER, Robert SCHLÖGEL
Portugal	Rui dos SANTOS IVO, Manuel NEVES DIAS
Finland	Hannes WAHLROOS, Pekka JÄRVINEN
Sweden	Birgitta BRATTHALL, Anders BROSTRÖM
United Kingdom	Keith JONES ¹ , Steve DEAN

Observers

Iceland	Rannveig GUNNARSDÓTTIR, Ingolf J PETERSEN
Liechtenstein	Brigitte BATLINER, Peter MALIN
Norway	Kai FINSNES, Gro Ramsten WESENBERG

¹ The UK will nominate a new member to replace Dr Jones following his election as chairman.